Apatinib and Chemotherapy Sequential Treatment With Cervical Cancer

Inclusion Criteria: * The pathological diagnosis of recurrent or metastatic cervical cancer; * Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1; * Life expectancy of more than 3months; * With normal marrow, liver and renal function： * blood routine examination ：HB≥90g/L，ANC ≥1.5×10\*9/L，PLT≥80×10\*9/L； * Biochemical examination: total bilirubin (TBil) of ≤1.5 upper normal limitation (UNL)，alanine aminotransferase (ALT) and aspartate aminotransferase (AST) of ≤2.5 UNL or ≤5 UNL ，acreatinine (Cr) of ≤ 1.25 UNL; creatinine clearance rate ≥ 45ml/min (Cockcroft-Gault); * With written informed consent signed voluntarily by patients themselves . * With good compliance and agree to accept follow-up of disease progression and adverse events. Exclusion Criteria: * Uncontrolled hypertension * Suffered from grade II or above myocardial ischemia or myocardial infarction, uncontrolled arrhythmias * With abnormal coagulation function， bleeding tendency or treating with thrombolysis and anticoagulation * History of clinically relevant major bleeding event (e.g. gastrointestinal hemorrhage, bleeding ulcer, occult blood ≥ (++), and vasculitis) =\< 3 months prior to randomization; * uncured the wound or fracture * Centrally located tumors of local invasion of major blood vessels, or Researchers think that patients may invade the important blood vessels and cause fatal bleeding (CT or MRI); * Factors affecting the oral medication (e.g. inability to swallow, chronic diarrhea and intestinal obstruction); * Urine protein \>++, or urine protein in 24 hours\> 1.0g * Accumulation of coelomic fluid (e.g. pleural effusion, ascites fluid, cardiac effusion) requiring treatment * History of uncontrolled psychotropic drug abuse or mental disorders; * Prior VEGFR inhibitor treatment ; * Other malignancy within Before or at the same time other than basal cell skin cancer, or carcinoma in situ of the cervix;